Immupeutics creates next‑generation immunomodulatory therapeutics that precisely target disease‑relevant immune pathways in autoimmune and inflammatory conditions. Using proprietary antibody discovery and engineered protein platforms, the company delivers highly specific biologics with improved safety, scalable manufacturing, and reduced dosing frequency for pharmaceutical and biotech partners.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with autoimmune and inflammatory diseases often lack therapies that precisely modulate the immune system, leading to inadequate disease control and significant side effects from broad‑acting drugs.
Solution
Immupeutics develops next‑generation immunomodulatory therapeutics that target specific immune pathways implicated in autoimmune and inflammatory conditions. By leveraging proprietary biologic platforms and precision engineering, the company creates molecules that selectively inhibit pathogenic immune cells while preserving normal immune function. Their pipeline includes antibody‑based agents and engineered protein therapeutics designed for high specificity, improved safety, and scalable manufacturing. Clinical programs focus on delivering disease‑modifying outcomes with reduced dosing frequency and minimized systemic toxicity.
Target Audience
Primary customers are pharmaceutical companies and biotech firms seeking licensed immunotherapy candidates, as well as clinical researchers focusing on autoimmune and inflammatory disease treatment.
Features
- Targeted biologic modalities (e.g., monoclonal antibodies, engineered proteins) that bind disease‑relevant immune receptors
- Proprietary platform for rapid antibody discovery and affinity maturation
- Integrated biomarker strategy to identify patient subpopulations most likely to benefit
- Scalable cell‑free manufacturing process to ensure consistent product quality
- Preclinical models demonstrating selective immune modulation with low off‑target activity